Patterns of real-world opioid prescribing in Australian general practice (2013–18)
Doreen Busingye
A C , Benjamin Daniels A B , Jonathan Brett B , Allan Pollack A , Josephine Belcher A , Kendal Chidwick A and Suzanne Blogg A
+ Author Affiliations
- Author Affiliations
A NPS MedicineWise, Level 7/418A Elizabeth Street, Surry Hills, NSW 2010, Australia.
B Medicines Policy Research Unit, Centre for Big Data Research in Health, Level 2, AGSM Building (G27), UNSW, Sydney, NSW 2052, Australia.
C Corresponding author. Email: dbusingye@nps.org.au
Australian Journal of Primary Health 27(5) 416-424 https://doi.org/10.1071/PY20270
Submitted: 12 November 2020 Accepted: 25 May 2021 Published: 15 September 2021
Journal Compilation © La Trobe University 2021 Open Access CC BY
Abstract
Little is known about private-market opioid prescribing and how Australian opioid policies impact prescribing across public and private markets in Australia. We aimed to investigate publicly subsidised and private-market opioid prescribing from 2013 to 2018. We used prescribing records from MedicineInsight, an Australian primary care database, to examine trends in prescriptions for non-injectable opioid formulations from October 2013 to September 2018. We examined annual opioid prescribing trends overall, by opioid agent, and by market (public and private). We further examined patterns of fentanyl patch prescribing focusing on co-prescribed medicines and use in opioid-naïve patients. Opioids accounted for 8% of all prescriptions over the study period and 468 893 patients were prescribed at least one opioid of interest. Prescribing rates for oxycodone/naloxone and tapentadol increased, whereas those for fentanyl patches, morphine and single-agent oxycodone decreased over the study period. Private-market prescribing rates of codeine (schedule 4) increased notably following its up-scheduling to prescription-only status. Among patients prescribed fentanyl patches, 29% were potentially opioid-naïve and 49% were prescribed another opioid on the same day. The private-medicines market is a small but growing component of opioid use in Australia and one way in which prescribers and patients can avoid access restrictions in the public market for these medicines. Although fentanyl patch prescribing declined, there is room for improvement in prescribing fentanyl patches among opioid-naïve patients, and co-prescribing of fentanyl patches with other sedatives.
Keywords: community, codeine, fentanyl, oxycodone, prescribing trends, tapentadol, co-prescribing, MedicineInsight.
References
Australian Bureau of Statistics (ABS) (2018) Socio-Economic Indexes for Areas. (ABS: Canberra, ACT, Australia) Available at http://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa [Verified 7 November 2019]Australian Government Department of Health (2012) Australian Statistics on Medicines 2012. Available at http://www.pbs.gov.au/info/statistics/asm/asm-2012 [Verified 25 November 2019]
Australian Government Department of Health (2016) Final decisions and reasons for decisions by delegates of the Secretary to the Department of Health Canberra.
Australian Government Department of Health (2019a) MBS Online: Medicare Benefits Schedule. Available at http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home [Verified 28 November 2019]
Australian Government Department of Health (2019b) PBS Frequently Asked Questions. Available at http://www.pbs.gov.au/info/general/faq [Verified 28 November 2019]
Australian Government Department of Health (2020) Pharmacist claiming of tramadol 50mg capsule prescriptions from 1 June 2020. Available at https://www.pbs.gov.au/pbs/news/2020/06/pharmacist-claiming-of-tramadol-50mg [Verified 19 May 2021]
Australian Therapeutic Goods Administration (2017) Scheduling Basics. Available at https://www.tga.gov.au/scheduling-basics [Verified 6 December 2019]
Australian Therapeutic Goods Administration (2018) Codeine information hub. Available at https://www.tga.gov.au/codeine-info-hub [Verified 6 December 2019]
Berterame S, Erthal J, Thomas J, Fellner S, Vosse B, Clare P, Hao W, Johnson DT, Mohar A, Pavadia J, Samak AKE, Sipp W, Sumyai V, Suryawati S, Toufiq J, Yans R, Mattick RP (2016) Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study. Lancet 387, 1644–1656.
| Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study.Crossref | GoogleScholarGoogle Scholar | 26852264PubMed |
Blanch B, Pearson SA, Haber PS (2014) An overview of the patterns of prescription opioid use, costs and related harms in Australia. British Journal of Clinical Pharmacology 78, 1159–1166.
| An overview of the patterns of prescription opioid use, costs and related harms in Australia.Crossref | GoogleScholarGoogle Scholar | 24962372PubMed |
Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ (2001) Chronic pain in Australia: a prevalence study. Pain 89, 127–134.
| Chronic pain in Australia: a prevalence study.Crossref | GoogleScholarGoogle Scholar | 11166468PubMed |
Busingye D, Gianacas C, Pollack A, Chidwick K, Merrifield A, Norman S, Mullin B, Hayhurst R, Blogg S, Havard A, Stocks N (2019) Data Resource Profile: MedicineInsight, an Australian national primary health care database. International Journal of Epidemiology 48, 1741–1741h.
| Data Resource Profile: MedicineInsight, an Australian national primary health care database.Crossref | GoogleScholarGoogle Scholar | 31292616PubMed |
Cairns R, Schaffer AL, Brown JA, Pearson S-A, Buckley NA (2020) Codeine use and harms in Australia: evaluating the effects of re-scheduling. Addiction (Abingdon, England) 115, 451–459.
| Codeine use and harms in Australia: evaluating the effects of re-scheduling.Crossref | GoogleScholarGoogle Scholar |
Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology 13, e58–e68.
| Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.Crossref | GoogleScholarGoogle Scholar | 22300860PubMed |
Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA (2015) The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Annals of Internal Medicine 162, 276–286.
| The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.Crossref | GoogleScholarGoogle Scholar | 25581257PubMed |
Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL (2015) Trends in Opioid Analgesic Abuse and Mortality in the United States. The New England Journal of Medicine 372, 241–248.
| Trends in Opioid Analgesic Abuse and Mortality in the United States.Crossref | GoogleScholarGoogle Scholar | 25587948PubMed |
Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R (2016) The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiology and Drug Safety 25, 521–538.
| The extent and correlates of community-based pharmaceutical opioid utilisation in Australia.Crossref | GoogleScholarGoogle Scholar | 26781123PubMed |
Finestone HM, Juurlink DN, Power B, Gomes T, Pimlott N (2016) Opioid prescribing is a surrogate for inadequate pain management resources. Canadian Family Physician Medecin de Famille Canadien 62, 465–468.
Gisev N, Pearson S-A, Dobbins T, Currow DC, Blyth F, Larney S, Dunlop A, Mattick RP, Wilson A, Degenhardt L (2018a) Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. BMJ Open 8, e025840
| Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol.Crossref | GoogleScholarGoogle Scholar | 30518593PubMed |
Gisev N, Pearson SA, Karanges EA, Larance B, Buckley NA, Larney S, Dobbins T, Blanch B, Degenhardt L (2018b) To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia? Pharmacoepidemiology and Drug Safety 27, 550–555.
| To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?Crossref | GoogleScholarGoogle Scholar | 29047196PubMed |
Giummarra MJ, Gibson SJ, Allen AR, Pichler AS, Arnold CA (2015) Polypharmacy and chronic pain: harm exposure is not all about the opioids. Pain Medicine 16, 472–479.
| Polypharmacy and chronic pain: harm exposure is not all about the opioids.Crossref | GoogleScholarGoogle Scholar | 25280054PubMed |
Grove A (2016) The Pharmaceutical Benefits Scheme: a quick guide. Available at https://www.aph.gov.au/About_Parliament/Parliamentary_Departments/Parliamentary_Library/pubs/rp/rp1516/Quick_Guides/PBS [Verified 28 November 2019]
Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M (2019) Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses. JAMA Network Open 2, e186007
| Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses.Crossref | GoogleScholarGoogle Scholar | 30657529PubMed |
Islam MM, Wollersheim D (2018) Variation in prescription opioid dispensing across neighborhoods of diverse socio-economic disadvantages in Victoria, Australia. Pharmaceuticals (Basel, Switzerland) 11, 116
| Variation in prescription opioid dispensing across neighborhoods of diverse socio-economic disadvantages in Victoria, Australia.Crossref | GoogleScholarGoogle Scholar |
Islam MM, McRae IS, Mazumdar S, Taplin S, McKetin R (2016) Prescription opioid analgesics for pain management in Australia: 20 years of dispensing. Internal Medicine Journal 46, 955–963.
| Prescription opioid analgesics for pain management in Australia: 20 years of dispensing.Crossref | GoogleScholarGoogle Scholar | 26602489PubMed |
Islam MM, McRae IS, Mazumdar S, Simpson P, Wollersheim D, Fatema K, Butler T (2018) Prescription opioid dispensing in New South Wales, Australia: spatial and temporal variation. BMC Pharmacology & Toxicology 19, 30
| Prescription opioid dispensing in New South Wales, Australia: spatial and temporal variation.Crossref | GoogleScholarGoogle Scholar |
Karanges EA, Blanch B, Buckley NA, Pearson S-A (2016) Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims. British Journal of Clinical Pharmacology 82, 255–267.
| Twenty-five years of prescription opioid use in Australia: a whole-of-population analysis using pharmaceutical claims.Crossref | GoogleScholarGoogle Scholar | 26991673PubMed |
Karanges EA, Buckley NA, Brett J, Blanch B, Litchfield M, Degenhardt L, Pearson S-A (2018) Trends in opioid utilisation in Australia, 2006–2015: insights from multiple metrics. Pharmacoepidemiology and Drug Safety 27, 504–512.
| Trends in opioid utilisation in Australia, 2006–2015: insights from multiple metrics.Crossref | GoogleScholarGoogle Scholar | 29280224PubMed |
Krzywinski M, Altman N (2013) Points of significance: error bars. Nature Methods 10, 921–922.
| Points of significance: error bars.Crossref | GoogleScholarGoogle Scholar | 24161969PubMed |
Lalic S, Ilomäki J, Bell JS, Korhonen MJ, Gisev N (2019) Prevalence and incidence of prescription opioid analgesic use in Australia. British Journal of Clinical Pharmacology 85, 202–215.
| Prevalence and incidence of prescription opioid analgesic use in Australia.Crossref | GoogleScholarGoogle Scholar | 30338545PubMed |
Lam T, Kuhn L, Hayman J, Middleton M, Wilson J, Scott D, Lubman DI, Smith K, Nielsen S (2020) Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018. Addiction (Abingdon, England) 115, 261–269.
| Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018.Crossref | GoogleScholarGoogle Scholar |
Larance B, Degenhardt L, Peacock A, Gisev N, Mattick R, Colledge S, Campbell G (2018) Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. Drug and Alcohol Review 37, S203–S205.
| Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses.Crossref | GoogleScholarGoogle Scholar | 29024092PubMed |
Martins SS, Sampson L, Cerda M, Galea S (2015) Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. American Journal of Public Health 105, e29–e49.
| Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature.Crossref | GoogleScholarGoogle Scholar | 26451760PubMed |
NPS MedicineWise (2006) Fentanyl patches (Durogesic) for chronic pain. Available at https://www.nps.org.au/radar/articles/fentanyl-patches-durogesic-for-chronic-pain [Verified 9 March 2020]
Poleshuck EL, Green CR (2008) Socioeconomic disadvantage and pain. Pain 136, 235–238.
| Socioeconomic disadvantage and pain.Crossref | GoogleScholarGoogle Scholar | 18440703PubMed |
Roxburgh A, Hall WD, Dobbins T, Gisev N, Burns L, Pearson S, Degenhardt L (2017) Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug and Alcohol Dependence 179, 291–298.
| Trends in heroin and pharmaceutical opioid overdose deaths in Australia.Crossref | GoogleScholarGoogle Scholar | 28826104PubMed |
Roxburgh A, Hall WD, Gisev N, Degenhardt L (2019) Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. Drug and Alcohol Dependence 205, 107533
| Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids.Crossref | GoogleScholarGoogle Scholar | 31704378PubMed |
Royal Australian College of General Practitioners (RACGP) (2017) Prescribing drugs of dependence in general practice, Part C2: The role of opioids in pain management. (RACGP: Melbourne, Vic., Australia) Available at https://www.racgp.org.au/FSDEDEV/media/documents/Clinical%20Resources/Guidelines/Drugs%20of%20dependence/Part-C2-The-role-of-opioids-in-pain-management.PDF [Verified 6 February 2019]
Schaffer AL, Karanges EA, Buckley NA, Wilson A, Degenhardt L, Larance B, Pearson SA (2019) Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study. Pharmacoepidemiology and Drug Safety 28, 97–105.
| Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study.Crossref | GoogleScholarGoogle Scholar | 30421838PubMed |
Shaheed CA, Maher CG, McLachlan A (2016) Investigating the efficacy and safety of over-the-counter codeine containing combination analgesics for pain and codeine based antitussives. Available at https://www.tga.gov.au/alert/review-efficacy-and-safety-over-counter-codeine-combination-medicines [Verified 22 July 2020]
Therapeutic Guidelines (2019) Chronic pain: pharmacological management. Available at https://tgldcdp.tg.org.au/viewTopic?topicfile=chronic-pain-pharmacological-management [Verified 29 November 2019]
Woodley M (2019) Mundipharma fined for misleading advertising of opioids. Available at https://www1.racgp.org.au/newsgp/professional/mundipharma-fined-for-misleading-advertising-of-op [Verified 23 March 2020]
